Â鶹´«Ã½

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

In the last 4 hours
Sefton Metropolitan Borough Council (Press Release)11:31
In the last 6 hours
Get Surrey10:16
Yesterday
PAHO (Press Release)16:35 1-Nov-24
Get Surrey10:53 1-Nov-24
Tameside Correspondent05:45 1-Nov-24
In the last 7 days
Belfast Live14:33 31-Oct-24
BioPharma Dive11:19 31-Oct-24
Nature.com06:58 31-Oct-24
Pharmacy Times14:30 30-Oct-24
Medpage Today14:15 30-Oct-24
Welsh Government (Press Release)11:35 30-Oct-24
Welsh Government (Press Release)11:05 30-Oct-24
Newswise (Press Release)08:22 30-Oct-24
This is Money05:41 30-Oct-24
pharmaphorum04:48 30-Oct-24
pharmaphorum04:27 30-Oct-24
Yahoo! UK & Ireland04:27 30-Oct-24
IFLScience11:41 29-Oct-24
The Nenagh Guardian10:30 29-Oct-24
My North Bay Now09:45 29-Oct-24
News-Medical.Net21:10 28-Oct-24
Paul-Ehrlich-Institut (Press Release)17:59 28-Oct-24
ScienceDaily17:38 28-Oct-24
Defense Visual Information Distribution Service16:15 28-Oct-24
UC San Francisco12:38 28-Oct-24
PRWeb (Press Release)10:37 28-Oct-24
Business Wire (Press Release)10:04 28-Oct-24
Pharmacy Times12:20 26-Oct-24
In the last month
Allure14:10 25-Oct-24
Muskegon Chronicle, Michigan14:10 25-Oct-24
Government of Canada (Press Release)13:42 25-Oct-24
Journal of American Medical Associations11:46 25-Oct-24
Condé Nast Traveler10:32 25-Oct-24
Devon Live10:04 25-Oct-24
CNET.co.uk09:31 25-Oct-24
NHS England (Press Release)07:37 25-Oct-24
Benzinga16:10 24-Oct-24
London South East04:29 24-Oct-24
GMA News03:52 24-Oct-24
London South East03:48 24-Oct-24
Grimsby Live03:03 24-Oct-24
GlaxoSmithKline (Press Release)02:10 24-Oct-24
McKnight's Long-Term Care News17:28 23-Oct-24
Forbes16:47 23-Oct-24
Pharmaceutical Technology16:07 23-Oct-24
Hull Live15:05 23-Oct-24
PharmTech.com13:15 23-Oct-24
Pharmacy Times13:08 23-Oct-24
American Journal of Managed Care13:00 23-Oct-24
Medpage Today12:38 23-Oct-24
American Journal of Managed Care12:20 23-Oct-24
Benzinga11:42 23-Oct-24
NHS England (Press Release)09:52 23-Oct-24
Business Wire (Press Release)09:03 23-Oct-24
The Mirror09:00 23-Oct-24
Get Surrey08:35 23-Oct-24
Think Global Health07:10 23-Oct-24
Daily Record05:54 23-Oct-24
pharmaphorum05:42 23-Oct-24
Get Surrey23:27 22-Oct-24
Business Wire (Press Release)16:46 22-Oct-24
Fortune13:18 22-Oct-24
Toronto Star12:22 22-Oct-24
Newswise (Press Release)12:00 22-Oct-24
Pharmacy Times09:50 22-Oct-24
Sherwood Forest Hospitals (Press Release)09:46 22-Oct-24
The Straits Times17:11 21-Oct-24
Global News13:09 21-Oct-24
American Journal of Managed Care12:41 21-Oct-24
Toronto Star12:32 21-Oct-24
Business Wire (Press Release)00:14 21-Oct-24
ScienceDaily20:40 20-Oct-24
Medpage Today17:38 20-Oct-24
Skeptical Raptor15:50 20-Oct-24
Medpage Today14:11 19-Oct-24
Pharmacy Times12:11 19-Oct-24
My London06:34 19-Oct-24
Pharmaceutical Technology19:41 18-Oct-24
The CT Mirror18:38 18-Oct-24
News-Medical.Net15:30 18-Oct-24
view more headlines
2 Nov 11:31

About our Respiratory Syncytial Virus news

Latest news on RSV, the respiratory syncytial virus affecting infants and young children, including updates on outbreaks, prevention, treatment, and research into this common but potentially serious illness in the UK and globally.

RSV is a highly contagious virus that causes respiratory tract infections, particularly in young children and older adults. In the UK, RSV accounts for around 33,000 hospitalizations annually in children under 5, according to recent data. The virus is also the most common cause of bronchiolitis and pneumonia in children under one year of age in the United States, as reported by the Centers for Disease Control and Prevention (CDC). While most RSV infections are mild, some cases can lead to severe complications, especially in premature infants, children with weakened immune systems, or those with underlying health conditions.

Our RSV news feed keeps you informed about the latest outbreaks and trends in RSV cases, as reported by healthcare providers, hospitals, and public health agencies in the UK and around the world. We cover stories on the impact of RSV on families and communities, as well as the strain it places on healthcare systems during peak seasons. Stay updated on the latest recommendations and guidelines from the UK Health Security Agency and the CDC for preventing the spread of RSV, such as frequent handwashing, avoiding close contact with infected individuals, and keeping high-touch surfaces clean.

In addition to prevention, our feed also covers the latest developments in RSV treatment and management. From supportive care measures like oxygen therapy and hydration to the use of antiviral medications and the potential for new RSV vaccines, we keep you informed about the options available for combating this illness. We also report on ongoing clinical trials and research studies aimed at improving RSV prevention, diagnosis, and treatment.

RSV has a significant impact on families, causing anxiety and stress for parents as they care for their sick children. Our feed includes personal stories and experiences shared by families affected by RSV, highlighting the human dimension of this illness. We also cover community initiatives and support groups that provide resources and comfort to those dealing with RSV.

As researchers work to better understand RSV and develop more effective interventions, our feed keeps you updated on the latest scientific findings and breakthroughs. From studies on the virus's structure and transmission to the development of novel therapies and vaccines, we provide comprehensive coverage of the ongoing efforts to combat RSV and improve public health outcomes.

In recent news, the UK government has issued a tender notice to purchase up to 6.3 million vaccines and treatments to protect babies and elderly people against RSV. The plan aims to secure supplies from GSK Plc, Pfizer Inc., and AstraZeneca Plc together with Sanofi, in time for the next winter season. The tender could see the purchase of up to 3.6 million products to protect older people, around 1.3 million for infants, and as many as 1.4 million for pregnant mothers, whose protection extends to their unborn babies.

The UK's move comes as countries race to secure supplies of the newly introduced RSV products, which have been developed after decades of research. The shots would be delivered between July 2024 and June 2026, with a possible two-year extension. The UK Health Security Agency is currently engaging with the market to assess its RSV needs and working with the National Health Service and the Department of Health and Social Care to implement a protection program.

In the European Union, several countries have also indicated their interest in working together to bulk purchase the RSV drugs. The European Commission is currently in the exploratory phase for possible joint procurements, highlighting the growing global demand for these life-saving interventions.

Our Â鶹´«Ã½ feed on RSV is constantly updated with the most relevant and reliable information from trusted sources, ensuring that you stay well-informed about this significant health concern affecting infants and young children. Whether you are a parent, healthcare professional, or simply interested in staying up-to-date on important health issues, this feed is your go-to resource for the latest news and developments related to RSV.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.